SCHEMBL4359245

SCHEMBL4359245

COc1ccc(F)cc1C(=O)c1cnc(NCCCCNS(=O)(=O)c2ccc(F)cc2)nc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 8/20 0.55
CDK4 P11802 7/20 0.55
CCND1 P24385 7/20 0.55
CDK2 P24941 7/20 0.55
MAPK1 P28482 1/20 0.43
BRAF P15056 3/20 0.43
ALDH1A1 P00352 2/20 0.43
EGFR P00533 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
MEN1 O00255 1/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41
RAF1 P04049 1/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HTR1A P08908 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
ADRA1D P25100 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4354535 0.93 CDK1 (0.53) CDK1CDK4CCND1CDK2BRAF
SCHEMBL4352534 0.90 CDK1 (0.59) CDK1CDK4CCND1CDK2EGFR
SCHEMBL3524063 0.89 CDK1 (0.59) CDK1CDK4CCND1CDK2EGFR
SCHEMBL4352509 0.86 CDK1 (0.56) CDK1CDK4CCND1CDK2EGFR
SCHEMBL4358772 0.85 CDK1 (0.56) CDK1CDK4CCND1CDK2EGFR
SCHEMBL4354378 0.79 CDK1 (0.51) CDK1CDK4CCND1CDK2
SCHEMBL3524565 0.79 CDK1 (0.50) CDK1CDK4CCND1CDK2EGFR
SCHEMBL13632163 0.78 CDK1 (0.63) CDK1CDK4CCND1CDK2EGFR
SCHEMBL4356298 0.77 CDK1 (0.54) CDK1CDK4CCND1CDK2MAPK1
SCHEMBL4357726 0.74 CDK1 (0.55) CDK1CDK4CCND1CDK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK1 6/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK1 6/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.